Danuglipron for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Nov 2020: Trial registered, NCT04617275
  2. 6 Jan 2021: Trial started, NCT04617275

The trials

NCT04617275: A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

State
Completed
Phase
Phase 2
People
151 taking part
Started
6 Jan 2021
Primary completion
17 Nov 2021
Arms
Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM, Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM, Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM, Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM, Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM, Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity
Results
Posted on the registry
  1. 5 Nov 2020: Trial registered
  2. 6 Jan 2021: Trial started
  3. 17 Nov 2021: Trial completed
  4. 8 Dec 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.